EQIPD logo

FACTS & FIGURES

Start Date
End Date

Contributions
IMI Funding
4 495 523
EFPIA in kind
5 094 139
Other
37 500
Total Cost9 627 162

Summary

Poor quality data is an issue in many research fields – all too often, results carried out in one organisation cannot be replicated elsewhere, and it is not always clear why. In medical research, consequences include poor decision-making resulting in higher failure rates and longer drug development times. There is therefore an urgent need for simple, sustainable solutions to improve data quality, and that’s where the EQIPD project comes in. Their goal is to deliver simple recommendations to facilitate data quality without impacting innovation.

The project team will start by analysing the variables in study design and data analysis that influence outcomes and establishing whether these are the same in academia and industry. They will then define the components of an EQIPD quality management system and work to achieve a consensus among different stakeholders on quality management recommendations for research. They will also assess the feasibility of the quality management system in prospective studies in the fields of neuroscience and safety.

Finally, the project will set up an online educational platform that will deliver certified courses in the principles and application of data quality and rigour. This, combined with the involvement in the project of many junior scientists, will pave the way for a cultural change in approaches to data quality in the medical research and drug development field.

Participants Show participants on map

EFPIA companies
  • AbbVie Inc., North Chicago, Illinois, United States
  • Boehringer Ingelheim International GmbH, Ingelheim, Germany
  • F. Hoffmann-La Roche Ltd, Basel, Switzerland
  • Institut De Recherches Servier S.A.S, Suresnes, France
  • Janssen Pharmaceutica NV, Beerse, Belgium
  • Novartis Pharma AG, Basel, Switzerland
  • Orion Corporation, Espoo, Finland
  • Pfizer Limited, Sandwich, Kent , United Kingdom
  • Psychogenics Inc
  • Sanofi-Aventis Research and Development, Chilly Mazarin, France
  • UCB Biopharma SPRL, Brussels, Belgium
Universities, research organisations, public bodies, non-profit groups
  • Charité – Universitätsmedizin Berlin, Berlin, Germany
  • Eberhard Karls Universitaet Tuebingen, Tuebingen, Germany
  • Imperial College of Science, Technology and Medicine, London, United Kingdom
  • Ludwig-Maximilians-Universitaet Muenchen, Munich, Germany
  • Rijksuniversiteit Groningen, Groningen, Netherlands
  • Stichting Buro ECNP , Utrecht, Netherlands
  • Stichting Katholieke Universiteit / Radboud university medical center, Nijmegen, Netherlands
  • The University Court Of The University Of Aberdeen
  • Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz, Mainz, Germany
  • Universität Bern, Bern, Switzerland
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Arlenda SA
  • Concentris Research Management GmbH, Fürstenfeldbruck, Germany
  • Noldus Information Technology BV, Wageningen, Netherlands
  • Paasp GMBH
  • Porsolt SAS
  • Science Exchange, Inc.
  • Synaptologics BV

CONTACT

Project coordinator
Malcolm MACLEOD
THE UNIVERSITY OF EDINBURGH
United Kingdom
malcolm.macleod[at]ed.ac.uk